PAMS
CERE

Pictet Asset Management (Switzerland)’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Pictet Asset Management (Switzerland)’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-7,577
Closed -$239K – 2043
2022
Q4 		$239K Buy
+7,577
New +$214K ﹤0.01% 1625

Other funds holding CERE

BCI
Bain Capital Investors Boston, Massachusetts $3.27B AUM 3.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Pictet Asset Management (Switzerland)'s CERE Position: Q1 2023 in Review

Pictet Asset Management (Switzerland) sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q1 2023, closing a stake of 7,577 shares — an estimated $239K sold.

Pictet Asset Management (Switzerland) first reported a position in CERE in Q4 2022 and held it in 1 quarter. The position peaked at $239K in Q4 2022. 119 funds tracked by Wall St. Rank hold CERE as of Q1 2023.

  • Pictet Asset Management (Switzerland) reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Pictet Asset Management (Switzerland) sold 7,577 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q1 2023, an estimated $239K.
  • Pictet Asset Management (Switzerland) first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q4 2022 and held it in 1 quarter.
  • Pictet Asset Management (Switzerland)'s Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $239K in Q4 2022.
  • 119 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q1 2023.

Based on Pictet Asset Management (Switzerland)'s 13F filing for Q1 2023, filed 10 May 2023.